ReviewCancer cell international2025
The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC).
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Therapeutic targeting of ROCK reverses EMT in lung cancer cells by impeding TAZ in Hippo signalling pathway.Molecular and cellular biochemistry · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- SIRT1 induces FOXO1/autophagy/NCOA4-induced ferroptosis and accelerates the progression of cerebral infarction by inhibiting the E2F1/NOTCH-1/YAP signaling pathway.Scientific reports · 2026Article
- AI-powered radiogenomics: imaging-driven diagnosis and discovery of cancer's molecular and cellular landscape.Molecular genetics and genomics : MGG · 2026Review
- EGFR-19del nuclear translocation increases HDAC7 expression inhibiting the Hippo pathway and exacerbating TKI resistance in lung adenocarcinoma.Theranostics · 2026Article
- LncRNA-Mediated miR-145 Sponging Drives FN1 and CCND1 Expression: Prognostic and Therapeutic Targets in NSCLC.Biomolecules · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer is one of the most common malignant tumours, with non-small cell lung cancer (NSCLC) being the predominant type. The morbidity and mortality rates of lung cancer are increasing worldwide. The Hippo signalling pathway is one of the eight classical human cancer signalling pathways, forming a complex signalling network regulated by intracellular and extracellular signals. Under physiological conditions, it plays a crucial role in inhibiting tumor development. MAIN TEXT: Inhibition of the Hippo signalling pathway leads to abnormal activation of its downstream core components, YAP/TAZ, which in turn enhances tumor cell proliferation, invasion, and migration. Recent studies have identified numerous small-molecule inhibitors that target key proteins within the Hippo signalling pathway, which is highly important for the treatment of tumors.
conclusionThis paper reviews the activation mechanisms of the Hippo signalling pathway, its crosstalk with other pathways, and potential therapeutic targets to provide new therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.